Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Multiple Myeloma 1Lymphoma 1Liposarcoma 1

Interventions

trametinib 8dabrafenib 7pembrolizumab 5Paclitaxel 5lenvatinib 4Radiotherapy, Intensity-Modulated 3Doxorubicin 3fosbretabulin 2cobimetinib 2cemiplimab 2atezolizumab 2Vemurafenib 2Sorafenib 2Nivolumab 2Bevacizumab 2zimberelimab 1tremelimumab 1selpercatinib 1sapanisertib 1sacituzumab govitecan 1pegfilgrastim 1fludarabine 1efatutazone 1durvalumab 1ceritinib 1cabozantinib 1aldesleukin 1abemaciclib 1Thyroidectomy 1Taxes 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Thyroid Carcinoma, Anaplastic × efatutazone × Clear all
NCT02152137 2025-01-27

Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer

Alliance for Clinical Trials in Oncology

Phase 2 Completed
19 enrolled 13 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡